BETA
Clinical-stage developer of graphene neural interfaces for brain mapping and adaptive neurostimulation.
INBRAIN Neuroelectronics is a Barcelona, Spain-based neurotechnology developer founded in 2020. Its graphene neural interfaces are designed to record and stimulate neural activity. The pipeline spans cortical brain mapping, an implantable Parkinson’s-focused therapeutic platform, and peripheral bioelectronics through subsidiary INNERVIA. Its website limits devices to investigational use and targets first product commercialization in 2027, subject to regulatory progress.
A University of Manchester-sponsored first-in-human brain-mapping study used the cortical interface during brain-tumor surgery at Salford Royal Hospital. The registry marks the study completed in June 2026 with ten enrolled; the company earlier reported eight surgically treated patients with no device-related adverse events through discharge. This small feasibility study does not establish long-term safety, Parkinson’s efficacy or broad clinical adoption. The company reports a 2023 FDA Breakthrough designation and 2024 TAP participation; neither constitutes marketing authorization.
INBRAIN announced a $50 million Series B in October 2024, led by imec.xpand, and a later September 2025 report put cumulative financing at $124 million. Documented collaborations include Merck KGaA for peripheral bioelectronics, Mayo Clinic for investigational clinical development, and Microsoft for AI research. MINIGRAPH work reported in October 2026 adds preclinical robotic implantation research. Scott Huennekens chairs the board, with Carolina Aguilar serving as CEO and co-founder.
[8][9][10][11][12][13][14][16][17][19][20][21][22][24][25][27]
INBRAIN’s graphene cortical interface and implantable Parkinson’s programs remain investigational. Company-reported Breakthrough Device designation and TAP participation facilitate development; they are not marketing authorization. The separate INNERVIA peripheral program does not inherit brain-interface study permissions. [23][11][1]
No matching FDA recall event was identified in the completed company/applicant, linked-identifier and product-name searches. [5][3]
Latest recorded source review: 2026-10-20.
Scope: selected product families.
No commercially marketed product portfolio has been established in the reviewed material.
NCT06368310: registry status completed in the 2026-06-30 update; 10 participants (actual). [7]
Thin, flexible surface interface being evaluated for intraoperative brain mapping. Human feasibility study registered as NCT06368310. [22][23][24][8][15]
Investigational / in developmentInvestigational / development use only; no commercial launch established.
Development program combining neural sensing, stimulation and adaptive computational control. Parkinson’s disease is the initial stated therapeutic focus. [19][23][18][16]
Investigational / in developmentInvestigational / development use only; no commercial launch established.
Subsidiary program developing graphene-based selective peripheral / vagus nerve interfaces with Merck KGaA. [17][23][11]
Investigational / in developmentInvestigational / development use only; no commercial launch established.
Consortium reported integrated neural interfaces, electronics and robotic implantation work. Accelerated ageing is not long-term human outcome evidence. [25]
NCT06368310 lists June 24, 2026 completion and ten actual enrolled. Full results are separate from registry status. [8]
Appointment as Chairman of the Board announced. [14]
Collaboration explores agentic AI using cloud and data infrastructure; not a launched autonomous therapy. [13]
Investigational collaboration announced; Boston subsidiary described in institutional release. Mayo financial interest disclosed. [12]
Round led by imec.xpand, with EIC Fund and other investors, to advance clinical development. [11]
University of Manchester reported use in brain-tumor surgery at Salford Royal Hospital. [24]
Company reports January 2024 entry into Total Product Life Cycle Advisory Program; no authorization inferred. [19]
Company reports designation for Parkinson’s-focused platform. Designation is not marketing clearance or approval. [19]
Partner announced graphene peripheral bioelectronics co-development. [17]
Accessed 10/29/2026